Haseltine is worried that molnupiravir, which induces mutations in the virus, will create many more variants, particularly if patients don't take the full course.
But Mark Denison, who has studied molnupiravir's mutations in viruses that survive multiple rounds of the med, says that they weaken the virus. Such mutations could cause drug-resistant viruses, but are less likely to create deadlier or more transmissible variants, he says.
• • •
Missing some Tweet in this thread? You can try to
force a refresh